Innovent Starts China Trial of PD-1/TIGIT Bispecific for Solid Tumors

Suzhou Innovent Bio started a China Phase I trial of an anti-PD-1/TIGIT bispecific antibody in advanced malignant tumors, especially GI cancers. Innovent said preclinical studies of IBI321 showed it retains the activity of a PD-1 inhibitor while suppressing TIGIT to enhance anti-cancer efficacy. TIGIT is an immune checkpoint receptor that plays a role in tumor immune surveillance. IBI321 was discovered through a collaboration between Innovent and Eli Lilly, but is being developed in  China  by Innovent. The Phase Ia study will evaluate dosing of IBI321 in several solid tumors. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.